Ubs Group Ag Regenxbio Inc. Put Options Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
Put Options
3 transactions
Others Institutions Holding RGNX
# of Institutions
180Shares Held
45.2MCall Options Held
103KPut Options Held
100K-
Black Rock Inc. New York, NY8.61MShares$105 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.78MShares$58.4 Million4.77% of portfolio
-
Jpmorgan Chase & CO New York, NY4.36MShares$53.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.42MShares$41.8 Million0.0% of portfolio
-
State Street Corp Boston, MA1.84MShares$22.5 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $528M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...